The comparative evaluation of the effects of new Antihistaminic drugs (Loratadin & Claritin Rhinitis treatment

Abstract:
Introduction
Allergic Rhinitis-chlorpheniramine-loratadineclavitin is one of the most important disease that occure commonly in east IRAN specially northeast, Khorasan. Approximately 10-15% of general population suffers from it´ s signs and symtpms. One of the best methods of allergic rhinitis treatments, that most is the most usual, is the of classic antihistaminic drugs such as: Chlorpheniramine, Pyrilamine and Diphenhydramine.These are common in the consumption of classic antihistaminics. There is more than a decade that is showed the Non Sedating Anti Histaminic Drugs are free from these side effects and do not show the CNS and anticholinergic disorders.
Methods
In this clinical study, the efficacy and adverse reactions of the Loratadine and it´ s registated product calles Claritin are compared with Chlorpheniramine on 90 patients. It has been performed in northeast IRAN and the study is a kind ofdouble blind, prospective studies.
Results
30 patients have recieved Chlorpheniramine, as the same for Loratadine and Claritin. Then the results are compared together. The results suggest than in the geographic condition of IRAN likewise, Lorataddine & specially Claritin can use as the powerful and effective nonsedating antihistamines that do not cross the blood brain barrier to show advers disorders and will be successful treatment of Allergic Rhinitis in the first line, specially in patients whom are sensitive to other antihistaminic dregs.
Discussion
Between them Claritin by it´ s acceptable clinical efficacy & lower side effects is preferable than Loratadine.
Language:
Persian
Published:
Journal of Medical Science, Volume:1 Issue: 2, 2005
Page:
6
magiran.com/p321982  
دانلود و مطالعه متن این مقاله با یکی از روشهای زیر امکان پذیر است:
اشتراک شخصی
با عضویت و پرداخت آنلاین حق اشتراک یک‌ساله به مبلغ 1,390,000ريال می‌توانید 70 عنوان مطلب دانلود کنید!
اشتراک سازمانی
به کتابخانه دانشگاه یا محل کار خود پیشنهاد کنید تا اشتراک سازمانی این پایگاه را برای دسترسی نامحدود همه کاربران به متن مطالب تهیه نمایند!
توجه!
  • حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران می‌شود.
  • پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانه‌های چاپی و دیجیتال را به کاربر نمی‌دهد.
In order to view content subscription is required

Personal subscription
Subscribe magiran.com for 70 € euros via PayPal and download 70 articles during a year.
Organization subscription
Please contact us to subscribe your university or library for unlimited access!